Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. News
  4. /
  5. Thirty Years of Alzheimer’s...

Thirty Years of Alzheimer’s Disease Research: Preventive Strategies Hold Promise for Risk Reduction While Cure Remains Elusive

October 9, 2024October 9, 2024checkorphan

Amsterdam, Netherlands – For more than 30 years, researchers have identified and quantified genetic and lifestyle factors for Alzheimer’s Disease (AD) and other dementias. Despite extensive research, the fundamental mechanisms behind these neurodegenerative diseases are still not fully understood, and effective management of AD is taking longer than expected. There is a critical need for novel approaches to combat this longstanding disease. A special supplement celebrating the 100th volume of the Journal of Alzheimer’s Disease (JAD), published by IOS Press (now part of Sage), provides a unique and insightful overview of the state of the art in the field.

Aging is associated with a gradual decline in cellular stability, leading to a decrease in overall health. In the brain, this process is closely linked with an increased risk of neurodegenerative diseases, including AD. Understanding the mechanisms of brain aging is crucial for developing strategies aimed at enhancing both lifespan and health span. Recent advancements in geroscience, the study of the relationship between aging and age-related diseases, have begun to redefine our understanding of AD, guiding the development of preventive medical strategies that target the aging process itself rather than merely addressing the symptomatic manifestations of the disease.

An editorial by Virginia Boccardi, MD, PhD, Department of Medicine and Surgery, Division of Gerontology and Geriatrics, University of Perugia, Italy, and colleagues, presents the following modifiable lifestyle interventions that might influence the disease’s progression or mitigate its risk factors:

  • Healthy diet: A nutritious diet is crucial for maintaining brain health
  • Regular exercise: Particularly aerobic activities like brisk walking for forty minutes three times a week
  • Social engagement: Prolonged social isolation can worsen neurological health and increase the risk of dementia
  • Quality sleep: Disruptions in sleep patterns can increase brain proteins linked to AD
  • Stress management: Chronic stress is associated with an increased risk of cognitive impairment
  • Mental Stimulation: Keeping the brain active helps build cognitive reserves and strengthens neural connections

Dr. Boccardi cautions, “While lifestyle prevention holds promise for reducing the risk of dementia, the practical challenges of achieving and sustaining behavior change, especially among high-risk populations, cannot be overlooked.”

“For more than 30 years, researchers have identified and quantified genetic and lifestyle factors for AD and other dementias,” adds William B. Grant, PhD, Sunlight, Nutrition, and Health Research Center, San Francisco, CA, USA, in a literature review. “Genetics plays an important role in the risk of AD. However, many lifestyle choices also play a part. It might be said that genetics loads the gun and lifestyle/nutrition pulls the trigger.”

The supplement also focuses on other approaches to achieve AD risk reduction and prevention. In Improving Cognition Without Clearing Amyloid: Effects of Tau and Ultrasound Neuromodulation, Jürgen Götz, PhD, Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, QLD, Australia, and colleagues, detail the use of neuromodulation to improve neuronal connectivity and activate plasticity as well as other mechanisms that mediate resilience and neural compensation.

The article Enhanced Brain Clearance of Tau and Amyloid-β in Alzheimer’s Disease Patients by Transcranial Radiofrequency Wave Treatment: A Central Role of Vascular Endothelial Growth Factor (VEGF), by Gary W. Arendash, PhD, RF Longevity, Phoenix, AZ, USA, and NeuroEM Therapeutics, Inc., Tampa, FL, USA, et al., presents findings from the first clinical study that evaluates the cytokine VEGF on brain clearance of tau and amyloid-β (Aβ) in human subjects, providing evidence for transcranial radiofrequency wave treatment as a new and non-invasive therapeutic that “clinically” modulates VEGF levels in and around meningeal lymphatic vessels, thus impacting their flow and ensuing removal of toxins such as Aβ and tau from the brain.

The supplement also focuses on AD assessment, genetic coding, environmental factors, symptoms, disease progression, treatment and clinical trials, early detection using recently developed approaches like biomarkers, and patient wellbeing and outcomes.

Commenting on the publication of the 100th volume of JAD, George Perry, PhD, Semmes Foundation Distinguished University Chair in Neurobiology, The University of Texas at San Antonio, TX, and Editor-in-Chief of JAD, says, “When my esteemed colleague Dr. Mark Smith and I founded JAD, we thought it essential to have a journal that embraced diversity of novel ideas rather than starting with dogmatic views. The dream of a journal focused on a community, committed to changing the course of AD, has been maintained for nearly 30 years by embracing and enhancing new ideas, engaging authorship and readership from the global AD community, and fostering careers in AD research.”

“IOS Press is extremely proud to be part of JAD’s notable achievement, publication of 100 volumes of this highly regarded and influential journal devoted exclusively to AD. This impressive milestone could not have been achieved without the vision and dedication of founding Editors-in-Chief Dr. George Perry and Dr. Mark Smith and the support of current Co-Editor-in-Chief Dr. Paula Moreira and the entire Editorial Board,” commented Rasjel van der Holst, Publisher at IOS Press.

 

Media Contact

Diana Murray
IOS Press
[email protected]
Office: 718-640-5678

Expert Contact

George Perry, PhD
Editor-in-Chief, Journal of Alzheimer’s Disease The University of Texas at San Antonio
[email protected]
Office: +1 210-458-8660

 

 

Posted Under
News Research
Tagged
AD research aging and disease Alzheimer Alzheimer Disease Alzheimer's Alzheimer's prevention Alzheimer’s disease amyloid-β basic research Behavior genetics Bioengineering biomarkers brain aging brain plasticity Cellular neuroscience Clinical medicine Clinical psychology clinical research clinical studies clinical study clinical trial clinical trials cognitive development Cognitive Health cognitive impairment Complex diseases degenerative disease dementia Developmental biology Developmental disorders Developmental neuroscience diet and brain health Discovery research Disease intervention disease prevention drug development Drug Discovery Drug research Drug targets drug therapy early detection Environmental methods gene targeting genetic disorders Genetic epidemiology Genetic factors genetic medicine genetic testing genetic variation genome-wide association studies genomics George Perry geroscience Health and medicine health care hospitals Human brain Human health immune system immunology IOS Press JAD Journal of Alzheimer s Disease Journal of Alzheimer’s Disease life sciences lifestyle factors Mark Smith medical treatments mental health mental stimulation molecular biology molecular genetics neglected disease neglected diseases neural mechanisms neurodegenerative disease neurodegenerative diseases neurodegenerative disorder neurodevelopmental disorders. neurological disorder Neurology Neuromodulation neuroscience orphan disease orphan drug Paula Moreira precision medicine preventive medicine public health quality sleep rare disease rare diseases regular exercise research research funding risk factors Scientific approaches Scientific publishing Sensory systems social engagement Social research Social studies stress management targeted drug delivery Tau proteins transcranial radiofrequency wave treatment translational medicine vascular endothelial growth factor VEGF

Related News

  • Parse Biosciences Powers Breakthrough Study Mapping Neuronal Pathways,
  • MIT’s 40Hz Brain Stimulation Shows Promise in Alzheimer’s Disease
  • Vigil Neuroscience’s TREM2-Targeted Alzheimer’s Treatment Show
  • University of Illinois Researchers Reveal New Gene Editing Tool SPLICE
  • Karolinska Institutet Study Reveals Link Between Lifestyle, Vascular H
More News

Clinical Trials

  • A Safety Study of the Administration of Mesenchymal Stem Cell Extracel
  • Wet Cupping Therapy in Ankylosing Spondylitis
  • A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemi
  • Autoimmune Hepatitis Cohort in China
  • Cold Agglutinin Disease Real World Evidence Registry
More Clinical Trials
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2025 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo